贝伐单抗联合多西他赛治疗晚期宫颈癌的临床疗效及安全性观察

目的 探讨贝伐单抗联合多西他赛治疗晚期宫颈癌的临床疗效及安全性。方法 收集2011年4月-2016年4月于西安医学院第二附属医院进行治疗的晚期宫颈癌患者75例作为研究对象进行回顾性分析，按照治疗方法的不同将其分为观察组43例和对照组32例。对照组患者仅使用多西他赛治疗，观察组在此基础上加用贝伐单抗。对两组患者临床疗效、不良反应、生活质量以及药物经济学进行考察与比较。结果 观察组总有效率和临床控制率均显著高于对照组，差异有统计学意义（P<0.05）。两组患者在血液系统、消化系统及其他毒副反应发生率方面均无显著差异。观察组生活质量改善总有效率为83.72%，对照组为62.50%，观察组显著高于对照组，差异有统计学意义（P<0.05）。观察组平均治疗费用为（8.3±1.0）万元，对照组为（1.8±0.6）万元，观察组显著高于对照组，差异有统计学意义（P<0.05）。结论 贝伐单抗联合多西他赛治疗晚期宫颈癌临床疗效优于多西紫杉醇单药，但费用高昂，需结合患者自身情况制定治疗方案。

Clinical efficacy and safety observation of bevacizumab combined with docetaxel in treatment of advanced cervix cancer

Objective To explore the clinical efficacy and safety of bevacizumab combined with docetaxel in treatment of advanced cervix cancer. Methods Seventy-five patients with advanced cervix cancer accepted in our hospital from April 2011 to April 2016 were selected and divided into observation group with 43 cases and control group with 32 cases according to different treatment methods. Patients in control group were given docetaxel, and patients in observation group were combined with bevacizumab on the basis of control group. The clinical efficacy, adverse reactions, life quality and pharmacoeconomics of two groups were observed and compared. Results The total efficacy and clinical control rate of observation group were all higher than control group with statistically significance (P<0.05). The adverse reaction rate of two groups had no difference. Total efficacy of life quality improvement was 83.72%, which was obviously higher than control group 62.50% with statistically significance (P<0.05). The average cost of observation group was (83±10) thousands, of control group was (18±6) thousands. The cost of observation group was obviously higher than control group with statistically significance (P<0.05). Conclusion Using bevacizumab combined with docetaxel in treatment of advanced cervix cancer has better effect clinical but costs much than docetaxel. We should set on treatment according to patients'' own situation.